Pay in 4 interest-free payments of $6.96 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Key results: On-treatment (no interruptions): Semaglutide (Wegovy): 57% lower risk of heart attack, stroke, or death Tirzepatide: Reference comparator Including treatment gaps: Semaglutide: 29% lower risk of major adverse cardiovascular events Tirzepatide: Higher event rates in this real-world analysis Why this matters: These data suggest semaglutide may have greater cardiovascular benefit than tirzepatidea provocative finding given both are highly effective for weight loss
Everyone who has dealt with weight fluctuations and unwanted weight gain has had a unique experience with their health that requires individualized attention
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) PubMed record
Its great for controlling calorie intake and managing weight
US$ 28.77
US$ 29.01
US$ 28.97
US$ 22.02
US$ 21.09
